Pf Magazine

Pf Magazine

Welcome to your go-to source for the newest updates, insights, events, job openings, and advancements in the pharmaceutical sector. Our platform provides you with the tools to stay informed on your schedule. Whether it's through print, online, or social media, we deliver the essential information you need to advance your career.

International
English
Magazine, Online/Digital

Outlet metrics

Domain Authority
27
Ranking

Global

#3382262

United Kingdom

#411101

Health/Biotechnology and Pharmaceuticals

#285

Traffic sources
Monthly visitors

Articles

  • 1 week ago | pf-media.co.uk | Emma Cooper

    Sapio Sciences, the science-aware™ lab informatics platform, has announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.

  • 2 weeks ago | pf-media.co.uk | Emma Cooper

    The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for chronic kidney disease, for use in the NHS. Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease.

  • 2 weeks ago | pf-media.co.uk | Hannah McGregor

    Gilead Sciences, Inc. will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, 30 May-3 June, and the 2025 European Hematology Association (EHA) Annual Congress, 12-15 June.

  • 2 weeks ago | pf-media.co.uk | Hannah McGregor

    Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, has announced the first patients have been dosed in the final cohort of its Phase 1b clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Parkinson’s disease is a devastating neurological condition affecting around 10 million people worldwide, for which there is currently no cure.

  • 2 weeks ago | pf-media.co.uk | Hannah McGregor

    NICE are consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (CLN2), a type of Batten disease. NICE draft guidance does not, at present, recommend the treatment’s use for future patients with this rare, life limiting disease due to its high price and the limited evidence of long-term effectiveness.

Contact details

Address

123 Example Street

City, Country 12345

Email Patterns

Contact Forms

Contact Form

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations